Topic: Insulin

Senator Bernie Sanders and the Senate Health, Education, Labor, and Pensions Committee address the rising costs of diabetes treatment and insulin. Dr. Keisha Lipska testifies that the food industry profits from making people sick while the drug industry profits from treating them. Sanders suggests banning junk food advertisements targeted at children as a preventative measure.

The final segment touches on the "Ozempic rebound" and the marketing of weight loss drugs. A musical mix addresses metabolic issues and insulin resistance. The hosts end with a message of support for producers regardless of their physical size or health struggles, emphasizing that they value their community's contributions above all else.

President Joe Biden delivered a speech in Florida, introduced by Congresswoman Debbie Wasserman Schultz, whom he mistakenly referred to as a Senator. During the address, Biden discussed global inflation, the war in Ukraine, and the cost of insulin, claiming he spoke to the inventor of insulin who died in 1941. He asserted that the United States has the lowest inflation rate of any major country.

The Inflation Reduction Act's $35 monthly cap on insulin costs goes into effect, but the benefit is limited strictly to patients on Medicare. This leaves approximately 20 million Americans with private insurance or no coverage still facing the highest insulin prices in the world, contradicting President Biden's claims of "taking on" Big Pharma.

President Biden delivers a series of warnings regarding the potential consequences of a Republican victory, claiming that caps on prescription drug costs and insulin would be "gone." He also references a 15 percent corporate tax rate, though his delivery of the figures is noted for its lack of clarity. The rhetoric echoes his 2012 "back in chains" comment regarding Wall Street deregulation.

A pharmaceutical industry insider reports the creation of a new "Obesity Division" at a major drug company to address the growing market for diabetes and weight-loss treatments. Statistics provided suggest that 100 million Americans are diabetic and 80 million are pre-diabetic, with nearly 46% of American children now affected by the condition due to poor dietary habits.

Critics of the Build Back Better plan argue that the legislation does not actually lower drug prices but instead uses taxpayer money to subsidize pharmaceutical companies. While the bill promises lower costs for insulin, the funds would flow directly to manufacturers like Pfizer and Moderna to cover the price gap.

Doctors at Health Partners in the Twin Cities are testing an intranasal insulin spray for Alzheimer's patients, which reportedly improves memory within 15 minutes. The hosts noted the segment's title "Hope for Joe" and suggested the news report eventually devolved into a "native ad" for the spraying device.

President Trump signed four executive orders aimed at drastically reducing prescription drug prices. These include requiring federal health centers to pass discounts on insulin and EpiPens directly to patients and allowing the legal importation of cheaper identical drugs from Canada. The lack of mainstream media coverage is attributed to the pharmaceutical industry's heavy advertising spend.

The hosts debate the economics of the pharmaceutical industry, comparing the current situation to the price gouging seen with insulin and EpiPens. They explore why big drug companies haven't simply bought the manufacturers of hydroxychloroquine to raise prices, noting that many of these manufacturers are based in India. The discussion shifts to the industry's primary focus on high-profit vaccines.

Austin City Councilmember Allison Alter is criticized for suggesting that needles found at homeless camps are primarily for "health reasons" like insulin. The city recently hired Matthew Doherty as a $100,000 consultant to address the homelessness crisis. The hosts point out that Doherty was previously fired by the Trump administration for failing to solve homelessness issues in California during his tenure under the Obama administration.

Congress held hearings on the skyrocketing cost of insulin, which has risen from $21 to $275 per vial since 1996. The hosts discuss how hospitals and insurance companies negotiate lump-sum budgets and then "back-fill" individual procedure prices to meet those arbitrary totals.

The hosts examine photos of Hillary Clinton from OZY Fest, pointing out a visible lump under her clothing. They speculate that she may be wearing medical equipment such as an insulin pump or a heart-assist device, suggesting she is concealing a serious health condition.

Listener Ryan Little shares information regarding a potential diabetes vaccine cure that has received little media coverage. Other donors request "moving karma" for new apartments and "jobs karma" for career transitions, accompanied by various show-specific jingles.

A producer and molecular biologist provides an overview of CRISPR technology, which allows for precise DNA editing. The system, derived from bacterial defense mechanisms against viruses, can be used to program yeast to produce beneficial proteins like insulin. The discussion touches on the rapid advancement of genetic engineering and its potential for both medical breakthroughs and controversial applications like "mutated rats."

The healthcare industry is shifting toward "bundled payments," where insurers pay a flat fee for a procedure like a hip replacement regardless of the actual hospital stay duration. Simultaneously, a Bloomberg report indicates potential price fixing in the insulin market, where three major companies have matched price increases to the decimal point over five years. These costs have doubled despite low national inflation.

A representative from the Salt Institute argues that federal dietary guidelines recommending low salt intake may be counterproductive and discriminatory. Research from Harvard Medical School is cited, suggesting that low-salt diets can increase insulin resistance, a precursor to type 2 diabetes. Furthermore, the theory posits that reducing salt leads to increased caloric consumption as the body attempts to satisfy its innate salt appetite, potentially worsening the obesity crisis.